Senhwa Biosciences Inc (生華科) yesterday said it has partnered with the US National Institutes of Health (NIH) to evaluate the efficacy of a new drug, dubbed Silmitasertib, for treatment of COVID-19.
The drug, developed by Senhwa Biosciences to treat cancers, such as bile duct cancer, medulloblastoma and pediatric brain tumor, showed promise in human tests to curb the ribonucleic acid (RNA) virus from proliferating.
“With the attribute, the drug is expected to help combat the novel coronavirus. We have not tested the drug on patients with COVID-19 in Taiwan, but the US NIH, looking forward to the drug’s efficacy, will run some trials in the US,” Senhwa Biosciences CEO Soong Tai-sen (宋台生) said by telephone.
The company would offer the drug for free to the US agency during the tests, but it is difficult to forecast when the trials would be completed, Soong said.
The New Taipei City-based firm has no intention of running human trials for COVID-19 treatment in Taiwan, as it has put all of its resources into its clinical trials on cancer treatment, but it is willing to partner with other companies and provide its drugs for free, Soong said.
The University of California San Francisco’s Quantitative Biosciences Institute last month identified 69 drugs or experimental compounds that might be effective in treating COVID-19, including the Silmitasertib, Soong said.
Silmitasertib could promote the formation of street granules by disrupting casein kinase 2, a protein kinase that performs diverse functions related to cell survival, thus preventing viruses from gaining ingredients such as nucleic acids to create a new virus, Soong said.
“Silmitasertib offers two advantages. First, its safety has been proven during our previous tests on about 300 people for cancer treatment. And second, we have about 120kg of Simitasertib in storage in the US, which would be convenient in terms of delivery to the NIH,” he said.
Given that Silmitasertib, unlike other potential new drugs under testing for COVID-19, such as remdesivir, does not directly attack the coronavirus or reduce lung damage, it is more likely to be used as a adjuvant drug, Soong said.
However, whether it would be effective and how it would be used with other medication would be determined by the NIH, Soong said.
Silmitasertib marks the only CK2 inhibitor present in clinical trials, he said.
The drug is undergoing a few human tests, including a Phase II trial for bile duct cancer in Taiwan, the US and South Korea, a Phase II clinical trial for medulloblastoma, sponsored by the National Institute of Health-Cancer Therapy Evaluation Program and the Pediatric Brain Tumor Consortium, and a Phase I study for advanced basal cell carcinoma, it said.
EQUAL SHARE: A row over Micron’s payouts coincides with a global debate about who deserves a cut of the sudden wealth generated by the artificial intelligence boom Micron Technology Inc is to provide its engineers in Taiwan a cash bonus of NT$1 million (US$31,600) plus equity rewards, as the company’s local unions are demanding an additional payout to reflect their contribution to the chipmaker’s blowout profits. The Idaho-based chipmaker said in a statement yesterday that its entry-level, Taiwan-based engineers’ average compensation would reach NT$3.4 million for the past fiscal year after the cash and equities awards. All employees in Taiwan would receive equities as part of the annual merit grants, the company added. Before the announcement, Micron’s unions asked for a one-time cash payout equal to about seven years
UNDER PRESSURE: Samsung taunted Apple with sarcastic posts on X during its launch, saying ‘reheating our leftovers,’ and ‘so far, so same’ Samsung Electronics Co launched a publicity campaign for its foldable phones, touting its hardware advantage and its early entry into the segment as it seeks to fend off a major challenge from Apple Inc. Apple on Wednesday unveiled the Duo, a folding US$1,999 iPhone aimed at shaking up a category long dominated by Samsung and Chinese companies such as Huawei Technologies Co (華為), whose devices have struggled to move beyond a niche audience. Apple adopted the passport-shaped design that Samsung Electronics unveiled less than two months ago with the Galaxy Z Fold 8, priced at US$1,899 and powered by Alphabet Inc’s Gemini
UNION DETERMINATION: Rejecting an offer for a one-time payout as an attempt to influence opinion, the union said a strike at the memory chip manufacturer is possible The Micron Taiwan workers’ union yesterday rejected a one-time payout unveiled by US-based Micron Technology Inc last week, saying it wants a long-term mechanism under which employees would share 15 percent of the company’s operating profits. While the union and the company are still in talks over the dispute, the reward package was proposed unilaterally by the employer without reaching an agreement with the union, union head Jerry Lin (林哲瑞) told reporters. Lin said he suspected the company was seeking to influence public opinion with the move. On Friday last week, Micron announced a reward package under which employees in Taiwan would receive
SOME CUSHION: Taiwan’s GDP is forecast to grow more than 11 percent this year, so the economy should be able to absorb the impact of a rate hike, an expert said With domestic inflation topping the 2 percent alert level for a fourth consecutive month last month and several major central banks around the world raising their key interest rates, Taiwan’s central bank is facing growing pressure to raise rates at its quarterly policymaking meeting on Thursday, economists said. At its June meeting, the central bank left interest rates unchanged for the ninth consecutive quarter, with the discount rate at 2 percent. Central Bank Governor Yang Chin-long (楊金龍) had said that the bank maintained a somewhat hawkish stance, with two board directors voicing support for a rate hike at the meeting. Cathay United
RSS